UNSPSC 51162710: Eprazinone

This classification denotes a mucolytic agent and expectorant with the molecular formula C24H32N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 883YNL63WU, chemically known as 1-propanone, 3-(4-(2-ethoxy-2-phenylethyl)-1-piperazinyl)-2-methyl-1-phenyl- but more generally known as eprazinone, which bears US NIH Compound Identifier 3245. European Medicines Agency schedules Eprazinone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06583MIG.

UNSPSC 51162710 Eprazinone, a Commodity code, shows minimal recent activity aligned with its nominal scope. The two recent state and local opportunities tagged with this code involve naloxone procurement and generic multi-source pharmaceutical distribution through cooperative purchasing, neither of which centers on eprazinone as a pharmaceutical ingredient or active agent. State and local governments soliciting under this code appear to be using it as a catch-all taxonomy marker for pharmaceutical and OTC product acquisitions rather than targeting eprazinone specifically. The issuing bodies include Seminole County, Florida (a county health authority) and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, which coordinates purchasing across multiple states including Oregon. The work being solicited spans emergency-response pharmaceuticals (naloxone for community health initiatives) and broad-based generic and OTC product supply contracts delivered through authorized drug wholesalers.

Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; vendors must include shipping and comply with E-Verify and drug-free workplace requirements. MMCAP issued RFP S1070000015802 on January 20, 2026 (response due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), with product availability required by May 15, 2026 and contract effectiveness July 1, 2026; vendors must maintain cGMP and DSCSA compliance, secure relationships with at least two wholesalers, and carry $5,000,000 commercial general liability coverage. The code shows little activity specific to eprazinone and does not demonstrate a concentrated procurement market under its intended pharmaceutical classification.